We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Alzheimer's disease Diagnosed by Infrared Analysis of Leucocytes

By LabMedica International staff writers
Posted on 13 Feb 2012
Infrared analysis of white blood cells may possibly be a promising way to diagnose Alzheimer's disease (AD) more accurately.

The technique, which is noninvasive, fast, and low-cost, measures how much infrared radiation is either emitted or absorbed by white blood cells and measured by spectroscopy. More...


Scientists at the Instituto de Estructura de la Materia (Madrid, Spain) used two-dimensional infrared spectroscopy to measure and compare the infrared radiation emitted or absorbed by the leucocytes of healthy controls, versus those of patients with mild, moderate, and severe Alzheimer's disease. A total of 50 patients with Alzheimer's and 20 healthy controls took part in the study and gave blood samples. The white blood cells or mononuclear leukocytes are thought to carry amyloid-ß peptide in Alzheimer patients.

The infrared spectrum of the film of leucocytes was measured with a 1725X spectrophotometer (Perkin-Elmer; Waltham, MA, USA) with high resolution and obtained as an average of 32 scans. The scientists found significant differences in the range of infrared wavelengths displayed between subjects, which were attributable to the different stages of formation of amyloid-ß structures in the blood cells. The results showed that, with this method, healthy controls could be distinguished from mild and moderate sufferers of Alzheimer's disease. The method is being explored as a tool for early diagnosis.

The analysis showed a good test performance: 90% sensitivity and 90.5% specificity for determinations involving mild and moderate AD patients and age-matched healthy controls, and 82.1% sensitivity and 90.5% specificity for determinations involving patients at the three AD stages, mild, moderate, and severe, and age-matched healthy controls. The study demonstrated that AD is associated with higher percentages of β-structure in mononuclear leukocytes than those in healthy age-matched controls.

The authors concluded that the method they used could potentially offer a more simple detection of alternative biomarkers of Alzheimer's disease. Mononuclear leukocytes seem to offer a stable medium to determine ß-sheet structure levels as a function of disease development. The measurements seem to be more sensitive for earlier stages of Alzheimer's disease, namely mild and moderate. The study was published online on January 21 2012, in the journal Analytical and Bioanalytical Chemistry.

Related Links:
Instituto de Estructura de la Materia
Perkin-Elmer



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.